Author:
Gentili Giuliano,Wirz Maria,Collotti Clelia,Vicari Giuseppe,Sernicola Leonardo,Verani Paola,Pizzocolo Giuseppe,Crovari Pietro,Icardi Giancarlo,Ortona Luigi,Tamburrini Enrica,Zanetti Alessandro
Publisher
Springer Science and Business Media LLC
Reference13 articles.
1. Benveniste R. E., Ochs H. D., Fischer S. H., Bess J. W. Jr.,Arthur L. O., Wedgwood R. J.: Screening for antibodies to LAV/HTLV-III in recipients of immunoglobulin preparations — Lanceti, 1091, 1986. (Letter).
2. Bremard-Oury C., Couroucé A. M., Badillet M., Huchet J., Schuller E., Bierling P., Jullien A. M., Habibi B.: Screening for antibodies to LAV/HTLV-III in recipients of immunoglobulin preparations — Lanceti, 1090, 1986. (Letter).
3. Centers for Disease Control (CDC): Safety of therapeutic immunoglobulin preparations with respect to transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus infection — Morbid. Mortal. wkly Rep.35, 231, 1986.
4. Centers for Disease Control (CDC): Update: serologic testing for antibody to human immunodeficiency virus — Morbid. Mortal. wkly Rep.36, 833, 1988.
5. Genesca J., Jett B. W., Epstein J. S., Wai-Kuo Shih J., Hewlett I. K., Alter H. J.: What do Western blot indeterminate patterns for human immunodeficiency virus mean in EIA-negative blood donors? — Lancetii, 1023, 1989.